Amgen Inc. announced that an experiment for ovarian cancer drug failed to demonstrate impressive results.
Trebananib expected to be utilized with Paclitaxel for the treatment of ovarian cancer. Sadly, the drug failed to fulfill the expectations of doctors.
It merely increased a month in the lifespan of the ovarian patients. Generally, ovarian patient survive till 18.3 months, however the new drug mounted up the ratio to only 19.3 months.
The chief purpose of this experiment is to assess the safety and effectiveness of the drug. Moreover, the patients who participated in this trail complained numerous other problems such as edema, nausea, hair loss and alopecia.
Sean E.Harper, the vice president of Research and Development at Amgen informed that the company had really high hopes with trebananib.
Moreover, Harper notified that it was the second stage of the three phases of the trail. Although the experiment failed but still the firm intends to carry on the trial.
In the first stage test the drug demonstrated significant results. It decreased the development of the disease and boosted up the survival of the patients.
Furthermore, the company stated that shortly it would present the data for publication in a medical journal.
The data demonstrates that nearly 14,000 women die with ovarian cancer every year in the United States. Unfortunately, majority of the patients are diagnosed at the last stage of the disease.
